Abstract
The use of cannabidiol (CBD) for treating brain disorders has gained increasing interest. While the mechanism of action of CBD in these conditions is still under investigation, CBD has been shown to affect numerous different drug targets in the brain that are involved in brain disorders. Here we review the preclinical and clinical evidence on the potential therapeutic use of CBD in treating various brain disorders. Moreover, we also examine various drug delivery approaches that have been applied to CBD. Due to the slow absorption and low bioavailability with the current oral CBD therapy, more efficient routes of administration to bypass hepatic metabolism, particularly pulmonary delivery, should be considered. Comparison of pharmacokinetic studies of different delivery routes highlight the advantages of intranasal and inhalation drug delivery over other routes of administration (oral, injection, sublingual, buccal, and transdermal) for treating brain disorders. These two routes of delivery, being non-invasive and able to achieve fast absorption and increase bioavailability, are attracting increasing interest for CBD applications, with more research and development expected in the near future.
Keywords: brain disorders, cannabidiol, inhalation, pharmacokinetics, systemic delivery
© 2023. The Author(s).
Similar articles
-
Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study.J Pharm Sci. 2021 Dec;110(12):3946-3952. doi: 10.1016/j.xphs.2021.08.012. Epub 2021 Aug 13.PMID: 34400185 Clinical Trial.
-
Pharmacokinetics of Cannabidiol in Sprague-Dawley Rats After Oral and Pulmonary Administration.Cannabis Cannabinoid Res. 2022 Oct 26. doi: 10.1089/can.2022.0121. Online ahead of print.PMID: 36301522
-
Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers.Eur J Pharm Biopharm. 2020 Sep;154:108-115. doi: 10.1016/j.ejpb.2020.06.021. Epub 2020 Jul 4.PMID: 32634571 Clinical Trial.
-
Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications.CNS Drugs. 2020 Aug;34(8):795-800. doi: 10.1007/s40263-020-00741-5.PMID: 32504461 Review.
-
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.Biomolecules. 2020 Nov 19;10(11):1575. doi: 10.3390/biom10111575.PMID: 33228239 Free PMC article. Review.
References
-
- Chayasirisobhon S. Mechanisms of action and pharmacokinetics of cannabis. Perm J. 2020;25:1–3.
-
- Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30(10):515–27. – DOI
-
- Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S, Cannabidiol in Dravet Syndrome Study G. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011–2020.
-
- Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, Paolini JL, Thiele EA. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57(10):1617–24. – DOI
-
- Mucke M, Phillips T, Radbruch L, Petzke F, Hauser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3:CD012182.

